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This study aimed to identify the barriers and facilitators to improve the use of health 
technology assessment (HTA) for the selection of medicines listed in the e-
Catalogue and the national formulary in Indonesia. 
Methods 
Semi-structured interviews were conducted to collect qualitative data. Purposive 
sampling was used to recruit the stakeholders consisting of policymakers, a 
pharmaceutical industry representative, healthcare providers, and patients. The data 
were analyzed using directed content analysis and following the COnsolidated 
criteria for REporting Qualitative studies (COREQ).  
Results  
The twenty-five participants interviewed agreed with the use of HTA for supporting 
the e-Catalogue and the national formulary and perceived the advantages of HTA 
implementation outweighed the disadvantages. Barriers mentioned were a lack of 
capability of local human resources, financial incentives, a clear framework and 
insufficient data. Strategies suggested to overcome the barriers were establishing 
(inter)national networks to build up capacity, setting up departments of HTA in 
several universities in Indonesia, and introducing a clear HTA framework. 
Facilitators mentioned were the ambition to achieve universal health coverage, the 
presence of legal frameworks to implement HTA in the e-Catalogue and the national 
formulary, and the demands for appropriate medicine policies. 
Conclusions  
Several barriers are currently hampering broad implementation of HTA in medicine 
pricing and reimbursement policy in Indonesia. Solutions to these issues appear 
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Introduction 
The 2015 transition from Millennium Development Goals to Sustainable 
Development Goals has triggered a shift in global health from service-specific 
targets to broader health system goals[1]. Target 3.8 of the Sustainable Development 
Goals explicitly states to achieve Universal Health Coverage (UHC)[2]. UHC will be 
accomplished when all people receive the healthcare services they need of sufficient 
quality and without suffering financial hardship. Therefore, the presence of UHC 
ideally will reduce or eliminate the proportion of out-of-pocket payments from 
healthcare expenditures[3]. Out-of-pocket payment, a direct payment to the 
healthcare providers at the time of service use, can drive an individual or a 
household below the poverty line[4]. In low middle-income countries (LMICs), the 
proportion of out-of-pocket payments in healthcare expenditures is still high, 
particularly for medicines, the number ranges from 50% to 90 %[5].  
Appropriate medicine policies combined with an implementation of health 
technology assessment (HTA) can facilitate countries to reduce the out-of-pocket 
payments for medicines on their way towards UHC. For instance, the United 
Kingdom (UK) and Thailand, as one of the oldest and the newest UHC examples 
respectively, have shown that the implementation of HTA supports their medicine 
policies[6]. Furthermore, the World Health Organization (WHO) highly recommends 
the use of HTA to facilitate the creation of a list of medicines in the medicine benefit 
package[7]. The WHO defines HTA as the systematic evaluation of properties, 
effects and/or impacts of health technologies and interventions[8]. HTA is a critical 
component of evidence-based policy decision making[7,9].  
In response to target 3.8 of the Sustainable Development Goals, the 
Government of Indonesia launched a new national health insurance system, which is 
called Jaminan Kesehatan Nasional – Kartu Indonesia Sehat (JKN-KIS) in 2014. 
The JKN-KIS aims to achieve UHC by 2020 and is managed by Indonesia‘s 
National Healthcare Security Agency, namely Badan Penyelenggara Jaminan Sosial 
Kesehatan (BPJS-Kesehatan)[10,11]. Additionally, several new medicine policies were 
introduced separately by the Ministry of Health to support the JKN-KIS. First, the e-
Catalogue was introduced as a national medicine pricing policy. The e-Catalgue 
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provides a list of medicines with specifications, prices, and suppliers. Second, the 
national formulary was compiled as a list of medicines covered by the BPJS-
Kesehatan[12]. The e-Catalogue and the national formulary have their own respective 
responsible committees, which were both established in 2013, a year before the 
implementation of the JKN-KIS. Although the e-Catalogue and the national 
formulary were established separately, in practice these policies are interrelated. 
Indonesian healthcare facilities can reimburse medicines listed in the national 
formulary based on its prices listed in the e-Catalogue[12-14].  
According to the national health insurance guidelines of Indonesia, an HTA 
approach should be used to select a health technology or intervention, including 
medicines, which will be covered by the BPJS-Kesehatan. This implies that HTA 
should be used in further developing the e-Catalogue and the national formulary. As 
a way forward, both may build on the guideline on the implementation of HTA in 
particular for medicines that the Department of Pharmacy and Medical Devices in 
the Ministry of Health of Indonesia introduced in 2013[15]. In detail, the national 
health insurance recommended that the use of HTA is developed and performed by 
an HTA committee installed by the Ministry of Health[12]. 
Indeed in 2014, several months after the implementation of the JKN-KIS, 
the Ministry of Health formed the HTA committee. The committee had eight senior 
health scientists and six employees of the Ministry of Health, and was supported by 
14 secretaries. The tasks of the committee were establishing a policy concept, 
guidelines, and the HTA committee itself to regulate the implementation of HTA[16]. 
In 2016, the HTA committee was reformed. The current HTA committee is 
composed of eight senior health scientists, one employee of the Ministry of Health, 
and supported by four secretaries. A technical staff with thirteen clinicians, two 
Ministry of Health employees, and one technician is now added to support the HTA 
committee tasks. Their current tasks are to define a guideline for HTA 
implementation, to establish the HTA committee and their work plan, to build a 
relationship with HTA committees in other countries, to assess the technologies or 
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However, although the HTA guideline was published in 2013 and the HTA 
committee had been installed in 2014, HTA has not been used in the development of 
the e-Catalogue and the national formulary. This might be one of the reasons why 
the use of the e-Catalogue and the national formulary could not help to reduce out-
of-pocket payments for medicines in Indonesia[18]. In 2014, the out-of-pocket 
payments comprised approximately half of the total health expenditure in Indonesia, 
and it has remained at a similar level since[19]. The proportion of out-of-pocket 
payments for medicines was 70% in recent years[20]. Furthermore, over the same 
period, the Ministry of Health reported that up to 40% of prescribed medicines were 
not listed in the NF[21]. Relevant stakeholders were interviewed to provide a better 
understanding of how to improve the implementation of HTA in Indonesia, with 
particular attention for suggestions on and barriers perceived regarding the use of 
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Materials and Methods  
Semi-structured interviews with multiple stakeholders were conducted to collect 
qualitative data. The COnsolidated criteria for REporting Qualitative studies 
(COREQ) checklist was followed in reporting the results[22]. 
Study Design and Participants 
The process applied in this study can be seen in the flowchart (Fig 1). First, a 
conceptual model (S1 Fig) was developed by RW, MP, WG, TF, and EB, based on a 
review of WHO documents on UHC, in particular concerning medicine policies and 
the use of HTA. Based on the conceptual model, initial list of themes and of 
questions (S1 Table) were created to get an overview of the development of 
medicine policies and the implementation of HTA in Indonesia. With the aim of 
testing the comprehensibility and appropriateness of the interview protocol (S1 
File), pilot interviews were conducted with three physicians, three pharmacists, and 
three patients. After revision based on the pilot, semi-structured interviews were 
then conducted with various stakeholders. Interviews were planned until saturation 
was reached. 
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A purposive sampling method was used to recruit stakeholders, which 
consisted of policymakers, medicine suppliers, healthcare providers, and patients in 
various places of Indonesia. Recruitment criteria were: stakeholders (policy makers, 
healthcare provider, industry representative) should have at least 5 years of relevant 
work experience. Physicians were not selected based on their specialization, because 
HTA would be implemented in the development of the national formulary, which is 
used by all healthcare providers regardless of their specialization. Both 
pharmaceutical industries approached produced medicines and medical devices and 
were responsible for distributing medicine to the healthcare facilities. Patients were 
selected based on the duration of their health insurance in Indonesia (at least 5 years) 
and their routine use of medicines (at least 5 years). In order to ensure that these 
patient criteria were met, participants were recruited from the BPJS-Kesehatan‘s 
chronic disease management program (Program pelayanan penyakit kronis, 
Prolanis).  
A priory estimation of the number of participants required to reach 
saturation was made. We estimated that at least twenty-two stakeholders should be 
approached based on at least two representatives for each group of policy makers, 
i.e., at least two pharmaceutical industry representatives, at least four interviewees 
from each group of healthcare providers, and at least four patients. The reason for 
having more interviewees in the groups of healthcare providers and patients was our 
interest in the practical issues of the implementation of medicine policy and the 
difficulties reported  for applying HTA for selecting medicine in the medicine 
policy. Potential participants were approached by email, phone and visit. 
Data analysis 
All interviews were audiotaped and then transcribed. The transcripts were 
independently coded by two authors (RW, SI) using MAXQDA version 12.3.2. 
Directed content analysis [23] was applied to systematically structure the content of 
the transcripts. The codes were compared, and in case of disagreements, items were 
discussed with AM, WG, MP, TF, and EB to reach a consensus. Twenty four themes 
were identified during coding process. The themes were then divided into two 
categories. The first concerned medicine pricing and reimbursement policy [18] and 
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the second the implementation of HTA. The current manuscript focused on the six 
themes (Table 1) related to the implementation of HTA.  
Table 1. List of themes 
No Themes 
1 Attitudes towards HTA implementation 
2 Advantages of HTA implementation in the e-Catalogue and the NF 
3 Disadvantages of HTA implementation in the e-Catalogue and the NF 
4 Barriers to HTA implementation 
5 Possible solutions to improve the implementation of HTA 
6 Promoting factors of HTA implementation 
 
The transcript interviews from six themes were coded to attain sub-themes. 
Saturation at the total level was assessed to identify the sub-themes. Saturation was 
considered to be reached when no new information was generated and when at least 
three interviewees mentioned the same concern for each sub-theme. These were 
checked by RW and SI.  
Ethical considerations 
The main author is Indonesian; therefore, an official research permit is not requested 
as stated in the relevant regulation of Indonesia‖. However, a written informed 
consent (S2 File) was obtained from all participants. Before the interviews, all 
participants understood that their participation was voluntary and that they were free 
to stop the interview at any time. All participants reviewed and consented to the 
verbatim transcript of their interview. Additionally, the research plan and the 
interviews to be conducted were reviewed by the University Medical Center 
Groningen Ethical Review Board, who deemed the study non-intrusive. 
Subsequently a formal waiver statement (S3 File) was provided, i.e., the study 
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Results  
Participants  
Aiming at about 22 final participants, a total of 51 (S2 Table) different individuals 
were approached during the recruitment process. Out of this number, 45 agreed to 
participate in this research. However, 9 withdrew after receiving the list of 
questions; another 7 decided to stop their interviews before they were finished, since 
they experienced difficulties in answering the questions, and were not confident 
about their answer; Furthermore 4 had no time for an interview, leaving a final 
number of 25 participants. Notably, this was more than initially aimed at. 
Twenty-five participants participated in this research (Table 2). They were 
policy makers (WHO members, HTA Committee, NF Committee and National 
Health Insurance Agency), a medicine supplier (a pharmaceutical industry 
representative), healthcare providers (physicians and pharmacists), and users 
(patients). All participants had the Indonesian nationality, except the WHO 
members. The policymakers, the pharmaceutical industry representative and 
healthcare providers each have more than 20 years of work experience in the 
Indonesian healthcare system. Furthermore, all interviewed patients had been 
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Policymakers      
WHO Members Male 50 25 NA Geneva  
 HTA Committee Female 53 28 28 Jakarta 
 HTA Committee Male 55 30 30 Jakarta 
 NF Committee Male 56 31 31 Yogyakarta 
JKN-KIS Agency Female 51 26 26 Jakarta 
JKN-KIS Agency Female 46 21 21 Jakarta 
Medicine Supplier      
Pharmaceutical Industry Male 54 29 29 Jakarta 
Healthcare Providers      
   Physician Male 58 33 33 Lombok 
   Physician Male 59 34 34 Makassar 
   Physician Male 66 41 41 Makassar 
   Physician Male 44 19 19 Surabaya 
   Physician Male 51 26 26 Jakarta 
   Physician Female 54 29 29 Yogyakarta 
   Pharmacist Female  53 28 28 Jakarta 
   Pharmacist Male 50 25 25 Manado 
   Pharmacist Male 39 14 14 Kendari 
   Pharmacist Male 42 17 17 Yogyakarta 
   Pharmacist Female 51 26 26 Lombok 
   Pharmacist Female 40 19 19 Makassar 
Users      
   Patient Male 53 NA 8 Makassar 
   Patient Male 63 NA 13 Makassar 
   Patient Female 59 NA 10 Makassar 
   Patient Male 57 NA 8 Makassar 
   Patient Female 63 NA 12 Makassar 
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Interviews and analysis of transcripts 
Semi-structured interviews were conducted face to face with 16 participants and 
through video calls with 9 participants between August 2016 and April 2017. One 
interview was conducted in English, while all others were in Bahasa Indonesia. The 
average time spent on each interview was circa one hour.  
Transcripts from the themes for HTA were checked to obtain sub-themes 
(S3 Table). For all six themes, more than three interviewees mentioned the same 
concern on each sub-theme.  It means that saturation could be confirmed at the total 
level. In table S3 we summarize the answers by respondent group, to make it easier 
for readers to understand the main concerns of each stakeholder group. The  
complete statement per theme can be found at raw materials (S4 Table). 
Findings per theme 
Theme 1: Attitudes towards HTA implementation  
All stakeholders demonstrated positive attitudes towards applying HTA to the 
development of the e-Catalogue and the NF. The main reason expressed for this 
attitude was the necessity of having appropriate medicine policies to support the 
JKN-KIS program in achieving UHC, in particular, reducing out-of-pocket 
payments for medicines. Moreover, participants perceived the advantages would 
outweigh the disadvantages.  
“If the HTA is applied to the NF or e-Catalogue I am very amenable. This will 
definitely be very good and provide great benefits” [Physician 5] 
Theme 2: Advantages of HTA implementation in the e-Catalogue and the NF 
Stakeholders recognized that the main advantage of HTA is to provide scientific 
evidence for decision makers to assess the value of a medicine. Additionally, the 
participants identified various other benefits when HTA would be implemented in 
the e-Catalogue and the NF. 
“The money allocated for the health sector is limited, especially for medicines. 
So, we can convince the government that more money should be allocated for 
medicines” [Policymaker 6] 
3
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The pharmaceutical industry representative mentioned that HTA would 
provide a ground for fair pricing in the e-Catalogue. Thus, pharmaceutical industries 
would not arbitrarily adapt their prices. 
“HTA can provide the rational price for bidding the medicines. Now, the 
pharmaceutical industry can bid the medicines as low as possible” 
[Pharmaceutical Industry] 
The policy makers, healthcare providers, and patients mentioned the use of 
HTA would reassure all stakeholders that the medicines listed in the NF were the 
best choice of medication. This would convince the government to allocate the 
money for providing the medicines listed in the NF, the physicians to prescribe the 
medicines listed in the NF, and also the patients to consume the medicines listed in 
the NF.  
“The advantage is that we may not doubt anymore about taking the medicine 
listed in the NF” [Patient 1] 
Theme 3: Disadvantages of HTA implementation in the e-Catalogue and the NF  
Among all interviewees, only a few could mention disadvantages of HTA 
implementation in the e-Catalogue and the NF. The most frequently mentioned 
disadvantage was the cost of developing the e-Catalogue and the NF probably would 
increase, in particular to pay HTA experts. In addition, complicated bureaucracy and 
lengthy processes for renewing the medicines listed in the e-Catalogue and the NF 
were also mentioned by the policy makers and healthcare providers.  
“People could say that this is too heavy or too bureaucratic, you need an 
excessively lengthy process for this” [Policymaker 1] 
Theme 4: Barriers to HTA implementation  
The participants identified various barriers that are currently hampering the 
implementation of HTA. The first barrier mentioned by all stakeholder categories, 
except the patients, was a lack of capability and a lack of capacity of local human 
resources. The reasons for this as explained by several interviewees were that HTA 
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“The science of HTA is still very new in Indonesia. Honestly, there are still 
many health workers and maybe including me who do not understand the 
application.”[Pharmacist 5]  
A second barrier mentioned by all categories of stakeholders, except the 
pharmaceutical industry representative, was a lack of incentives. The stakeholders 
considered that currently little resources are available for paying the HTA experts, 
holding HTA seminars, and performing HTA research.  
“There is a significant financial problem for the experts, since the HTA 
Committee still depends on the state budget and the standard fees established 
by the Ministry of Finance must be adhered to. We cannot give the fee 
according to their (HTA experts) expertise because there is a maximum salary 
that can be awarded when using the state budget”. [Policymaker 3] 
A third barrier mentioned by the policy makers pharmaceutical industry 
representative and healthcare providers was a lack of a clear framework of how to 
implement using HTA results in the medicine policy, in particular in the e-Catalogue 
and the NF. These interviewees mentioned that a clear framework is needed since 
multiple professions have to cooperate to initiate HTA, perform HTA, assess and 
appraise HTA results, and translate findings into policy advise.  
“We do not yet have a clear path of how to apply HTA. Moreover, HTA 
requires a variety of professions. This will create a conflict of interest. If there 
are no clear guidelines, all will be based on the point of view of each 
profession”. [Pharmaceutical Industry] 
A fourth barrier mentioned by the policy makers and healthcare providers 
was insufficient data for conducting HTA studies. The HTA committee members 
interviewed perceived the insufficient data was caused by difficulties to access data 
on the national scale. National data gathering is managed by the JKN-KIS agency. 
The JKN-KIS agency representative explained that the insufficient data was caused 
by unclarities regarding the data needed for conducting HTA studies. Furthermore, 
the health care providers also mentioned that the healthcare registry data, for 
instance, individual patient data, have not been integrated in the national scale.  
“The number of provinces in Indonesia makes it difficult to integrate all the 
data that could be used for HTA studies, so, we still need time to collect the 
data needed by the HTA researchers” [Policymaker 6] 
3
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Theme 5: Possible solutions to improve the implementation of HTA  
The participants provided a variety of possible solutions to address the barriers 
hampering the implementation of HTA. The policy makers indicated a necessity to 
establish a good network to build up the capacity. For instance, students and 
researchers could be endorsed to conduct HTA studies using Indonesian data. 
Currently, the Ministry of Health only depends on the state budget to establish the 
HTA committee and to build the capacity. Pharmaceutical industries could be 
encouraged to provide additional means.  
“The government must obtain alternative funding instead of depending on the 
state budget to implement HTA. I think the pharmaceutical industry can 
actually be asked to provide additional income in order to finance experts or 
researchers of HTA studies”. [Policymaker 2] 
The pharmaceutical industry representative suggested the creation of a clear 
framework for performing HTA implementation. The healthcare providers 
recommended that the government would provide more training and seminars to 
improve the capability of human resources regarding HTA. The healthcare 
professionals similarly suggested opening more HTA departments in universities in 
Indonesia. Finally, patients expected the government and all stakeholders to have a 
good collaboration in terms of introducing the implementation of HTA in Indonesia. 
“The government through the health ministry should establish guidelines to 
have a clear path to implement HTA” [Pharmaceutical Industry] 
“The government should encourage universities to open HTA departments. So, 
we can learn the topics of HTA in a good curriculum”. [Pharmacist 1] 
I hope all stakeholders can work together and find a good solution to start the 
implementation of HTA in Indonesia”.  [Patient 6] 
Theme 6: Promoting factors for the implementation of HTA 
The participants identified several promoting factors for the implementation of 
HTA. First of all, the main factor mentioned by all stakeholder‘s category was that 
the JKN-KIS aims to achieve UHC. Several stakeholders perceived that the use of 
HTA is suitable for countries that are on their way to implement UHC. A second 
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implementing JKN-KIS, in particular to select medicines which will be covered by 
the BPJS-Kesehatan. Therefore, the use of HTA is mandatory in developing the list 
of medicines in the e-Catalogue and the NF. A third promoting factor was the use of 
the current e-Catalogue and the NF without HTA implementation have not helped 
sufficiently to reduce out-of-pocket payments for medicines.  
"The supporting factor is that we are implementing an international scale 
program, which is Universal Health Coverage. The HTA program is highly 
recommended World Health Organization for countries implementing UHC 
program.” [Physician 6] 
“The regulation of Indonesia stated that HTA should be conducted for 
selecting the healthcare services needed. Indonesia is lucky since it has a legal 
aspect, whereas Vietnam does not have this. In some European countries it is 
also not present”. [Policymaker 2] 
“We need a list of medications which were well selected at the NF. This was to 
avoid the doctors prescribed medicines not listed in the NF and also to prevent 
patients from spending money because they have to buy medicines that are not 
covered by BPJS Kesehatan”. [Pharmacist 5] 
3
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Discussion 
This study provides insight into the current implementation of HTA in Indonesia in 
the development of the e-Catalogue and the National Formulary as medicines 
policies, as perceived by multiple stakeholders. To the best of our knowledge, no 
previous interview-based studies on this topic were performed in South East Asia. 
All interviewees showed a positive attitude towards the application of HTA to the e-
Catalogue and the NF. The interviewees expected HTA could optimize the use of 
the e-Catalogue and the NF to reduce out-of-pocket payments and, subsequently, to 
achieve UHC in Indonesia. Furthermore, the stakeholders identified the advantages 
of applying HTA to both the e-Catalogue and the NF were greater than the 
disadvantages. However, interviewees mentioned that the application of HTA has 
the potential to increase costs for the development of the e-Catalogue and the NF. 
Specifically, this study clarifies the barriers, possible solutions, and facilitators of 
HTA implementation.  
Interestingly, some interviewees perceived that the use of HTA would 
increase the cost for developing the e-Catalogue and the NF. However, other 
participants mentioned that the use of HTA for the e-Catalogue and the NF could 
improve efficiency. Our previous study[18] has revealed that the e-Catalogue and the 
NF have not been fully utilized in the healthcare facilities and were often ignored by 
stakeholders. This implies that unnecessary spendings have been allocated for 
producing these two medicine policies. For the e-Catalogue, HTA might support the 
setting of minimum prices as one of the problems mentioned was that the final 
tendered prices of medicines were too low and might jeopardize quality and 
distribution of medicines. Such prices would then reflect reasonable price levels for 
each medicine, in terms of costs per quality adjusted life years gained[24]. In 
addition, interviewees mentioned that the use of HTA in the NF might help to 
provide transparency and evidence for selecting medicines listed in the NF, and that 
this could improve its acceptance and use by stakeholders. Several LMICs aiming to 
achieve UHC have to consider a way to limit or choose the available healthcare 
services and HTA is one of the tools to support reimbursement package decision 
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how the use of HTA is helpful in selecting the medicines listed in their medicine 
reimbursement list. Thus, a more effective way of achieving UHC is achieved[6].   
Several barriers to implement HTA were identified and reported in the 
results. The two most important barriers mentioned were a lack of local human 
resources and a lack of financial incentives. Previous studies[25] based on surveys 
stated that these barriers were the major barriers in 19 LMICs, including Vietnam as 
Indonesia's neighboring country. In addition, for other neighboring countries, such 
as Philipines and Malaysia, capacity building and financial incentives were also 
identified as significant barriers for implementing HTA in their medicine policies[26-
28]. In the current study, the interviewees offered several possible solutions to 
overcome these obstacles. An interesting solution suggested by the NHI agency was 
that the HTA committee could establish a network with other countries that have a 
well-established system, and with international HTA organizations.  In response to 
financial barriers, the authors support a solution suggested by the HTA committee 
that the Government of Indonesia could provide an alternative funding instead of 
depending on the state budget. The interviewees recognized the need of HTA but 
also wondered how it should be funded. We think the implementation as achieved 
by the HTA committee of Thailand may serve as an example. The Committee 
obtains funding from the Thai Health Promotion Foundation, an institution 
established by the Ministry of Health of Thailand to collect health funding through 
two percents surcharge levied on the excise tax of alcohol and tobacco. This 
institution also obtains its funding from pharmaceutical companies and international 
HTA agencies[29]. 
The main important factor mentioned to support HTA implementation in 
the e-Catalogue and the NF was a mandate in the Presidential Decree[30], which 
stated that the development of medicine policies must be based on the HTA study. 
This implies the HTA must be applied in the e-Catalogue and the NF development. 
Based on a previous international study[31], this implication can lead to a continuous 
development of the capacity building for local human resources.  
Conducting interviews allowed the researcher to obtain detailed 
information about personal feelings, perceptions and opinions from the participants 
3
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indepedently from other group members. Moreover, all ambiguities and incomplete 
answers could be clarified and followed up. Several steps were taken to ensure a 
good research practice during the data compilation and analysis stages. The 
sampling processs used to select participants and the interview guide were compared 
with recommendations published in the COREQ[22]. 
Though a variety of stakeholders were interviewed in this study, not all 
groups of stakeholders were equally large and it turned out hard to find industry 
representatives willing to participate. Notably, only one pharmaceutical industry 
representative agreed to participate. Nonetheless, the interviewee was relatively 
experienced and was a leader in several pharmaceutical associations in Indonesia.  
While saturation was reached at the level of the total group, it could not be 
ensured for smaller groups of stakeholders, namely industry and policy makers.  
Also, this research contained interviews with a specific group of patients, namely 
from the Prolanis. The main reason for this was that participants from this group 
were relatively easy to find and recruit. These patients affiliated to the Prolanis 
group were considered as being able to provide more information than other patients 
since they had already routinely consumed medicines and had actively used public 
health insurance in Indonesia for a significant time period. It is relevant to note that 
quite a few people did not feel comfortable to participate or withdrew their consent 
after having seen the questions for the interview. This may indicate that a substantial 
part of stakeholders is not very familiar with the concepts discussed during the 
interviews and/or considers the topics as hard to discuss.   
Recognizing the current barriers and facilitators identified to apply HTA in 
the development of the e-Catalogue and the national formulary could assist decision 
makers in developing a blueprint for the further implementation of HTA in 
Indonesia. This could also be relevant for international policymakers in other LMICs 
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Conclusions 
Several barriers are currently hampering the implementation of HTA to support 
medicine pricing and reimbursement policies in Indonesia. However, solutions for 
these issues are under consideration and facilitators do exist. The major barriers to 
the implementation of HTA are a lack of capacity of local human resources and a 
lack of (financial) incentives. Possible solutions to address these issues would be to 
establish a network with other countries that have a well-established system, and 
with international HTA organizations. A major opportunity to support the 
implementation of HTA in the e-Catalogue and the NF is the existing legal 
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Supporting Information 
S1 Fig. Conceptual framework 
 






Many countries aim to reform their national health insurance to reach universal 
health coverage. Nowadays, 58 countries are using universal health coverage 
besides Indonesia. Before 2014, various health insurance schemes covered health 
insurance for Indonesian society. As of 2014, all these schemes were integrated 
and organized under one agency called BPJS-Kesehatan. The main goal of this 
insurance is to achieve universal health coverage by 2019. The problem with 
BPJS-Kesehatan was budgetary constraints, with the highest expenditure being 
pharmaceuticals. The national formulary was used to organize medicines. HTA 
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S1 Table. Initial list of themes and of questions 
NO THEMES NO QUESTIONS 
1 The development 
of medicine policy 
and national 
health insurance 
1 Do you know how long the HTA Committee, NF 
Committee, and NHI Agency have existed? 
2 How many committee members? 
3 What are their professions? 
4 What are their duties? 
5 Why do they exist? 
6 What is their function? 
7 What is their role in supporting UHC? 
8 How is the NHI different from previous health 
insurance (Askes, Jamkesmas, etc)? 
9 How many people are covered by the NHI Agency 
currently? 
2 Medicines policy 
for UHC 
10 What medicines policy or policies should be created 
to support UHC? 
11 Are you involved in creating the NF and other 
medicines policies to support UHC? 
3 Users Perspective  12 Do you know how the National Formulary is 
compiled? 
13 Do you agree with the NF? 
14 Do you have policy recommendations to maximize 
the use of HTA? 
15 Do you have other policy recommendations for 
prescribing drugs? 
4 Obstruction and 
promoting factors 
of HTA 
16 What is/are the advantage(s) using HTA in 
medicines policy? 
17 What is/are the disadvantage(s) using HTA in 
medicines policy? 
18 What is/are the facilitator(s) implementing HTA in 
medicines?  
19 What is/are the barrier(s) implementing HTA in 
medicines?  
20 What should other stakeholders do to solve them? 
And which ones? 
21 What should the government do? 
5 The biggest 
burden of disease 
and medicine 
expenditure 
22 What is the most widespread disease in Indonesia? 
23 How much money is allocated for medicines in the 
national health system? 
24 What medicines are allocated more money? (Why?) 
6 Prescriptions not 
in NF 
25 Have you ever received prescriptions for drugs not 
in the NF (How frequently and why)? 
26 Which medicines do you receive most often that are 
in the NF? 
27 Do you agree when doctors prescribe medicines not 
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S4. Table. Raw materials 
Raw material can be found in this link below: 
https://doi.org/10.1371/journal.pone.0225626.s005  
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S1 File. Interview protocol 
List of Questions for participants (excluding patients) 
 
1. What do you know about the JKN-KIS program? Which points can you 
explain: 
a. Implementing Agency;  
b. When executed; 
c. Implementation goals;  
d. Other personal information according to participants? 
2. As far as you know, what public health insurance programs have been 
implemented prior to the implementation of the JKN-KIS program? 
a. Implementing Agency; 
b. The policy/program that they imposed to control medicines? 
3. Do you know why all public health insurance programs are integrated into JKN-
KIS? 
4. What are the medicine policies/programs imposing on the JKN-KIS? 
a. The role or the functions of the policies 
b. What are the policy-making processes? 
c. Are you involved in the policy-making process? 
d. Who is involved in the policy-making process? 
e. Do you agree with the program/policies? 
f. Do you think there is/are stakeholder(s) harmed by that policy? For 
example, doctors, pharmacists, the pharmaceutical industry, patients, etc. 
g. Do you think the policy is based on the latest scientific evidence? 




GOI  = Government of Indonesia 
HTA  = Health Technology Assessment 
JKN-KIS  = a National Health Insurance scheme of Indonesia 
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5. What do you know about the HTA? 
a. Implementing Agency;  
b. When executed; 
c. Implementation goals;  
6. Do you think the HTA should be applied to the medicine policies on the JKN-
KIS?  
7. In your opinion, what are the advantages and disadvantages of using HTA in 
medicine policies on JKN-KIS?  
8. In your opinion, what are the supporting and inhibiting factors for the use of 
HTA on medicine policies in JKN-KIS? 
9. In your opinion, what solutions should be found to implement the HTA on 
medicine policies in JKN-KIS? 
a. What should be done by all stakeholders (policymakers, doctors, 
pharmacists, drug companies, patients, etc.) 
b. What should be done by the GOI? 
10. Have you ever found prescriptions not in the medicine policies on JKN-KIS? 
a. Do you know why this occurred? 
b. Do you agree with prescriptions not being in the medicines policy? 
c. What medicines are most commonly prescribed that are not part of the 
policies of JKN-KIS? 
d. Do you have any suggestions to overcome this? 
11. Do you know how much money is allocated for medicines to support the JKN-
KIS program? 
a. Do you know which drugs are allocated the largest budget? 
12.  Do you know what is the most widespread disease in Indonesia? 
a. Do you know how much money is allocated to cope with this disease? 
13. Do you have other comments regarding this research? 
3
2 
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List of Questions for Participants (excluding patients) in 
Bahasa
 
1. Apa yang anda ketahui tentang JKN-KIS. Point yang dapat anda jelaskan 
yaitu: 
a. Instansi apa yang melaksanakan? 
b. Kapan mulai dilaksanakan? 
c. Apa tujuan dilaksanakan? 
d. Informasi lain yang dianggap perlu disampaikan dari partisipan 
2. Sejauh yang anda ketahui, program jaminan kesehatan publik apa saja yang 
dilaksanakan sebelum diberlakukannya JKN-KIS? 
a. Instansi apa yang melaksanakan? 
b. Apakah anda tahu kebijakan/ program apa yang mereka terapkan untuk 
mengontrol obat? 
3. Apakah anda tahu, mengapa seluruh program jaminan kesehatan publik 
berintegrasi ke JKN-KIS? 
4. Apa sajakah kebijakan/ program yang sudah diberlakukan oleh pemerintah pada 
program JKN-KIS?  
a. Apakah anda tahu fungsi kebijakan/ program tersebut? 
b. Apakah anda tahu bagaimana proses pembuatan kebijakan tersebut? 
c. Apakah anda terlibat dalam proses pembuatan kebijakan tersebut? 
d. Siapa-siapa saja yang terlibat dalam proses pembuatan kebijakan tersebut? 
e. Apakah anda setuju dengan kebijakan tersebut? Mengapa? 
f. Menurut anda, adakah stakeholders (Dokter, Apoteker, Perusahaan obat, 
pasien, dll) yang dirugikan dengan kebijakan tersebut?  
g. Menurut anda, apakah kebijakan tersebut telah melalui bukti ilmiah 
mutakhir? 
h. Menurut anda, adakah usulan kebijakan lain yang sebaiknya diterapkan? 
Pengertian Istilah: 
HTA =  Health Technology Assessment/ Penilaian Teknologi Kesehatan; 
JKN-KIS  = Program Jaminan Kesehatan Nasional di Indonesia; 
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5. Apa yang anda ketahui tentang HTA? 
a. Instansi apa yang melaksanakan? 
b. Kapan mulai dilaksanakan? 
c. Apa tujuan dilaksanakan? 
6. Menurut anda, apakah HTA sebaiknya diterapkan pada kebijakan obat yang 
sudah diterapkan pemerintah untuk mendukung JKN-KIS? 
7. Menurut anda, apa keuntungan dan kerugian menggunakan HTA pada 
kebijakan obat yang sudah diterapkan pemerintah?  
8. Menurut anda, apa faktor pendukung dan faktor penghambat menggunakan 
HTA pada kebijakan obat yang sudah diterapkan pemerintah?  
9. Menurut anda, soulusi apa yang sebaiknya dilakukan untuk melaksanakan HTA 
pada kebijakan obat yang sudah diterapkan pemerintah? 
a. Apa yang sebaiknya dilakukan oleh para stakeholders (pembuat kebijakan, 
dokter, apoteker, perusahaan obat, pasien, dll)? 
b. Apa yang sebaiknya dilakukan oleh pemerintah?  
10. Pernahkah anda menemukan peresepan obat di luar kebijakan obat yang sudah 
diterapkan pemerintah? 
a. Apakah anda setuju dengan peresepan obat diluar kebijakan obat yang 
sudah diterapkan pemerintah? 
b. Obat apa yang paling sering diresepkan diluar kebijakan obat yang sudah 
diterapkan pemerintah? 
c. Apakah anda tahu, bagaimana cara mengatasi hal tersebut? 
11. Apakah anda tahu berapa banyak anggaran belanja obat yang dialokasikan 
untuk mendukung JKN-KIS? 
a. Apakah anda tahu obat apa yang mendapatkan anggaran terbesar? 
12. Apakah anda tahu penyakit yang terbesar di Indonesia? 
a. Apakah anda tahu berapa banyak anggaran untuk obat yang dialokasikan 
untuk mengatasi penyakit tersebut? 
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A List of Questions for Patients 
  
1. Do you know about JKN-KIS, which is part of BPJS-Kesehatan? Could you 
explain briefly it? 
2. Are you a participant in JKN-KIS? 
3. When were you be a participant in JKN-KIS? 
4. What health insurance did you use before JKN-KIS? 
5. For how long were you a participant in that insurance? 
6. Are you currently taking any medication?  
a. When was the last time you took the drugs? 
b. What drugs did you take? 
7. Did you also take that medicine when using your previous insurance? 
8. Do you feel a difference when taking medication of JKN-KIS compared with 
medication of your previous health insurance? 
a. Which one is cheaper?  
b. Which are more efficacious? 
c. Which one do you like, and think is better? 
9. Is there a difference, do you feel, in terms of service between JKN-KIS and 
your previous health insurance? 
a. Are there differences when seeing doctors? 
b. Is there a difference when conducting laboratory checks or other checks? 
10. Do you know about UHC? Could you explain briefly what you know? 
a. Do you agree with the GOI‘s target of reaching UHC in 2019?  
b. Do you think it can be achieved? 
c. Are there any suggestions from you in order to achieve the UHC?  
11. Do you know about NF? Could you explain briefly about that? 
a. Do you know how NF is created? 
Key terms: 
GOI  = Government of Indonesia 
HTA  = Health Technology Assessment 
JKN-KIS  = a National Health Insurance scheme of Indonesia 
UHC  = Universal Health Coverage 
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b. Do you agree with NF? 
c. What medications do you often receive which are in NF? 
d. Have you ever received prescriptions not in the NF? How often? Why? 
e. Do you agree with prescriptions not in the NF? Why? 
f. Do you have a policy recommendation in prescriptions? 
12. Do you know about HTA? Could you explain briefly what you know? 
a. Do you think the HTA can be used for medicines policy in Indonesia? 
b. In your opinion, what is the advantage of using HTA in determining the 
choice of medicines? 
c. In your opinion, what are the disadvantages of using HTA in determining 
the choice of medicines? 
d. In your opinion, what are the promoting factors in implementing an HTA 
for drug selection? 
e. In your opinion, what are the obstacles in implementing an HTA for drug 
selection? 
f. In your opinion, what should be done by stakeholders to resolve this? 
g. In your opinion, what should the government do? 
13. Do you have suggestions for improving medicines policy? 
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A List of Questions for Patients in Bahasa 
1. Apakah anda tahu tentang jaminan kesehatan nasional yang dikelola oleh BPJS-
Kesehatan? Bisakah anda Jelaskan sedikit tentang hal itu? 
2. Apakah anda anggota BPJS-Kesehatan? 
3. Kapan anda mulai menjadi anggota BPJS-Kesehatan? 
4. Asuransi apa yang anda gunakan sebelum menjadi anggota BPJS-Kesehatan ? 
5. Berapa lama anda menjadi anggota asuransi tersebut? 
6. Apakah anda mengkonsumsi obat saat ini? 
a. Kapan terakhir kali anda mengkonsumsi obat? 
b. Obat apa? 
7. Apakah obat tersebut juga anda konsumsi dengan menggunakan asuransi yang 
sebelumnya? 
8. Apakah ada perbedaan yang anda rasakan ketika menggunakan obat dari BPJS 
dengan obat dari asuransi anda sebelumnya? 
a. Yang mana yang lebih murah? 
b. Yang mana yang lebih berkhasiat? 
c. Yang mana yang anda suka dan anggap lebih baik? 
9. Apakah ada perbedaan yang anda rasakan dari sisi pelayanan pada Asuransi 
BPJS dan Asuransi yang anda gunakan sebelumnya? 
a. Apakah ada perbedaan ketika bertemu dengan dokter? 
b. Apakah ada perbedaan ketika melakukan cek laboratorium atau 
pemeriksaan lainnya? 
10. Apakah anda tahu tentang Univeral Health Coverage (UHC)/ Jaminan kesehatan 
secara menyeluruh? Bisakah anda Jelaskan sedikit tentang hal itu? 
a. Apakah anda sependapat dengan pemerintah Indonesia yang ingin 
mencapai UHC di tahun 2019? 
b. Apakah anda pikir itu bisa dicapai? 
c. Apakah ada saran dari anda untuk mencapai UHC tersebut? 
11. Apakah anda tahu tentang Formularium Nasional (Fornas)? 
a. Apakah anda tahu bagaimana Fornas dibuat? 
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c. Obat apa yang sering anda terima yang ada di dalam Fornas? 
d. Pernakah anda menerima obat di luar Fornas? Seberapa sering? Kenapa? 
e. Apakah anda setuju ketika dokter menuliskan obat diluar formularium 
nasional? Kenapa? 
f. Apakah anda memiliki rekomendasi kebijakan dalam penulisan obat? 
12. Apakah anda tahu tentang Health Technology Assessment (HTA) / Penilaian 
Teknologi Kesehatan? Bisakah anda Jelaskan sedikit tentang hal itu? 
a. Menurut anda, apakah HTA dapat digunakan untuk kebijakan obat di 
Indonesia? 
b. Menurut anda, apa keuntungan menggunakan HTA dalam menentukan 
pilihan obat? 
c. Menurut anda, apa kerugian menggunakan HTA dalam menentukan 
pemilihan obat? 
d. Menurut anda, apa faktor pendukung dalam menjalankan HTA pada 
pemilihan obat? 
e. Menurut anda, apa faktor penghambat dalam menjalankan HTA pada 
pemilihan obat? 
f. Apa yang harus dilakukan oleh pemangku kebijakan untuk menyelesaikan 
itu? 
g. Menurut anda, apa yang harus dilakukan oleh pemerintah? 
13. Apakah anda memiliki saran untuk meningkatkan kebijakan obat? 
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S2 File. Informed consent 
Lembar penjelasan dan persetujuan kepada partisipan 
Peluang dan tantangan kebijakan obat pada program JKN-KIS untuk mencapai 
Cakupan Perlindungan Semesta / Universal Health Coverage (UHC) 
 Saya Riswandy Wasir, Mahasiswa Program Pascasarjana (S3) Departemen 
Epidemiologi, Univerity Medical Center Groningen (UMCG), University of 
Groningen, Netherlands. Saat ini saya sedang melakukan penelitian yang berjudul 
―peluang dan tantangan kebijakan obat pada program JKN-KIS untuk mencapai 
cakupan perlindungan semesta‖.  
 Pemerintah Indonesia telah menerapkan skema asuransi kesehatan nasional 
(JKN-KIS) yang terintegrasi dimulai pada tahun 2014. Asuransi kesehatan yang 
dikelolah oleh BPJS-Kesehatan dimaksudkan sebagai pengganti seluruh asuransi 
kesehatan publik sebelumnya. Peta jaminan kesehatan nasional yang dirilis oleh 
pemerintah menyatakan bahwa program JKN-KIS diupayakan mencapai cakupan 
perlindungan semseta/ Universal Health Coverage (UHC) pada tahun 2019. 
Organisasi Kesehatan Dunia/ World Health Organization (WHO) menyatakan 
bahwa bukan hanya kepesertaan yang menjadi indikator tercapainya cakupan 
perlindungan semesta, tetapi juga kualitas pelayanan.  
 Berbagai upaya telah dilakukan oleh pemerintah dan para pemangku 
kebijakan untuk meningkatkan mutu pelayanan JKN-KIS. Pada sektor obat, 
pemerintah Indonesia telah menerapkan formularium nasional. Manfaat Fornas yaitu 
sebagai acuan penetapan penggunaan obat dalam JKN-KIS, serta meningkatkan 
penggunaan obat yang rasional, dapat juga mengendalikan mutu dan biaya 
pengobatan, serta mengoptimalkan pelayanan kepada pasien Namun, Hasil evaluasi 
awal yang dilakukan oleh Direktorat Jenderal Bina Farmasi dan Alat Kesehatan 
(Dirjen Binfar dan Alkes) memperlihatkan bahwa kesesuaian obat yang digunakan 
di rumah sakit dengan formularium nasional berkisar antara 60 – 86 %. Hal ini 
memperlihatkan bahwa masih ditemukan cost-sharing, suatu kondisi dimana peserta 
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termasuk obat. Salah satu Indikator tercapainya cakupan perlindungan semesta 
(UHC) menurut WHO adalah tidak adanya cost-sharing. 
 Kami, melakukan penelitian ini untuk mengidentifikasi peluang dan 
tantangan kebijakan obat pada program JKN-KIS untuk mencapai cakupan 
perlindungan semesta. Penelitian ini akan melibatkan beberapa pemangku 
kepentingan yang dianggap memiliki peran dalam membuat kebijakan, 
mengimplementasikan serta merasakan dampak dari kebijakan tersebut antara lain 
sebagai berikut: 
No Partisipan Peran 
1 Organisasi Kesehatan Dunia (WHO) Pembuat Kebijakan skala Internasional 
2 Komite HTA Pembuat kebijakan skala nasional 
3 Komite Formularium Nasional  Pembuat kebijakan skala nasional 
4 BPJS-Kesehatan Penyelenggara JKN-KIS dan Pembayar 
5 Perusahaan Farmasi Pemasok obat 
6 Dokter Penyedia pelayanan kesehatan 
7 Apoteker Penyedia pelayanan kesehatan 
8 Pasien Peserta JKN-KIS/ Pengguna 
 
 Penelitian akan dilaksanakan dengan metode wawancara bebas terpimpin 
(semi-structured interview). Daftar pertanyaan, surat kesediaan berpartisipasi 
(informed consent), dan pedoman wawancara akan diberikan oleh peneliti kepada 
partisipan sehari sebelum wawancara atau pada waktu yang telah ditentukan 
bersama. Durasi waktu pada saat melaksanakan wawancara mendalam yaitu sekitar 
1 (satu) jam. 
I. Kesukarelaan untuk ikut penelitian 
Bapak/ Ibu/ Saudara bebas memilih keikutsertaan dalam penelitian ini tanpa ada 
paksaan. Bila bapak/ ibu/ saudara sudah memutuskan untuk ikut dapat juga 
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J. Prosedur Penelitian 
Apabila Bapak/ Ibu/ Saudara bersedia berpartisipasi dalam penelitian ini, 
diminta menandatangani lembar persetujuan ini rangkap dua, satu untuk Bapak/ 
Ibu/ Saudara simpan, dan satu untuk peneliti. Prosedur selanjutnya adalah : 
5. Penelitian akan dilaksanakan dengan metode wawancara terpimpin (semi-
structured Interview) sesuai dengan kesepakatan dan kenyamanan bapak/ 
ibu/ saudara menggunakan alat perekam. 
6. Peneliti akan mentranskrip hasil wawancara setelah melaksanakan 
interview dengan partisipan. 
7. Hasil transkrip akan diperlihatkan kembali kepada partisipan untuk 
mengklarifikasi hasil wawancara. 
8. Hasil transkrip yang telah disepakati antara peneliti dan partisipan akan 
diproses oleh peneliti beserta tim peneliti lainnya untuk kemudian dijadikan 
data kualitatif yang akan di publikasi. 
K. Kewajiban partisipan 
Sebagai partisipan, Bapak/Ibu/Saudara berkewajiban mengikuti aturan atau 
petunjuk penelitian seperti yang tertulis di atas. Bila ada yang belum jelas, 
Bapak/ Ibu/ Saudara bisa bertanya lebih lanjut kepada peneliti. 
L. Risiko  
Penelitian ini tidak menyebabkan risiko yang berbahaya, karena peneliti tidak 
melakukan intervensi apapun. Risiko ketidaknyamanan atau dampak yang 
mungkin akan diterima yaitu merasa bosan dengan banyaknya 
pertanyaan- pertanyaan dari peneliti dan kerugian waktu selama 
diwawancarai oleh peneliti. 
M. Manfaat dan Keuntungan 
Manfaat dan keuntungan yang bapak/ ibu/ saudara dapatkan adalah kesempatan 
dan kebebasan untuk menjelaskan mengenai apa yang anda rasakan terhadap 
kebijakan obat pada program JKN-KIS. Penelitian ini nantinya akan diupayakan 
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N. Kerahasiaan 
Semua informasi yang berkaitan dengan identitas partisipan akan dirahasiakan 
dan hanya akan diketahui oleh peneliti. Data hasil penelitian akan disimpan 
dan didokumentasikan oleh peneliti serta hanya digunakan untuk 
kepentingan ilmiah. Hasil penelitian akan dipublikasikan tanpa identitas 
partisipan. 
O. Kompensasi 
Bapak/ ibu/ saudara akan mendapatkan souvenir sebagai wujud terima kasih 
peneliti atas partisipasinya dalam penelitian ini. 
P. Informasi  Tambahan 
Bapak/ ibu/ saudara diberi kesempatan untuk menanyakan semua hal yang 
belum jelas sehubungan dengan penelitian ini. Bila sewaktu-waktu terjadi 
kekeliruan atau membutuhkan penjelasan lebih lanjut, Bapak/ ibu/ saudara 
dapat menghubungi Riswandy Wasir pada no HP: +62-81225835007 atau 














The implementation of health technology assessment (HTA) in Indonesia
 
 108 | Moving Forward to Achieve Universal Health Coverage in Indonesia   
Persetujuan keikutsertaan dalam penelitian 
(informed consent) 
Saya yang bertandatangan dibawah ini: 
Nama  :........................................................................ 
Alamat  : ....................................................................... 
Nomor Hp  : ....................................................................... 
E-mail : ....................................................................... 
Umur  : ....................................................................... 
Pekerjaan  : ....................................................................... 
Pendidikan Terakhir : ....................................................................... 
Peran partisipan :  
9. Anggota Organisasi Kesehatan Dunia / World Health Organization (WHO) 
10. Komite Penilaian Teknologi Kesehatan / Health Technology Assessment 
(HTA) 
11. Komite Formularium Nasional 
12. Instansi Penyelenggara Asuransi Kesehatan Nasional 
13. Perusahaan Farmasi 
14. Dokter 
15. Apoteker 
16. Pasien  
Menyatakan bahwa, semua penjelasan tersebut telah disampaikan kepada saya 
sebagai partisipan dan semua pertanyaan saya telah dijawab oleh peneliti. 
Saya mengerti bahwa bila memerlukan penjelasan, saya dapat menanyakan 
kepada saudara Riswandy Wasir sebagai peneliti utama. 
Dengan menandatangani formulir ini, saya setuju untuk ikut serta dalam penelitian 
ini 
Tanggal: Tanggal: 
Tanda Tangan Partisipan Tanda Tangan Peneliti 
 
Nama Jelas: ……………………………. 
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3
2 
Chapter three 
 
